BACKGROUND & AIMS: Defective apoptosis of lamina propria T cells (LPTs) is involved in the pathogenesis of Crohn's disease. Survivin, a member of the inhibitors of apoptosis family, prevents cell death and regulates cell division. Survivin has been studied extensively in cancer, but little is known about its role in Crohn's disease. METHODS: LPTs were isolated from mucosal samples of patients with Crohn's disease or ulcerative colitis and healthy individuals (controls). LPTs were activated with interleukin-2 or via CD3, CD2, and CD28 signaling, and cultured at 42°C to induce heat shock. Survivin expression was assessed by immunohistochemistry, confocal microscopy, and immunoblotting; survivin levels were reduced by RNA interference. Cell viability, apoptosis, and proliferation were measured by trypan blue exclusion, annexin-V/7-Aminoactinomycin D staining, and uptake of [3]thymidine, respectively. RESULTS: LPTs from patients with Crohn's disease had higher levels of survivin than LPTs from patients with ulcerative colitis or controls. RNA knockdown of survivin in LPTs inhibited their proliferation and promoted apoptosis. Levels of survivin were low in LPTs from patients with ulcerative colitis and controls as a result of ubiquitin-mediated proteasome degradation. In LPTs from patients with Crohn's disease, survivin bound to the heat shock protein (HSP)90, and therefore was resistant to proteasome degradation. Incubating LPTs with 17-N-allylamino-17-demethoxygeldanamycin, an inhibitor of HSP90, reduced levels of survivin and induced apoptosis. CONCLUSIONS: Levels of survivin are increased in LPTs from patients with Crohn's disease (compared with ulcerative colitis and controls) because survivin interacts with HSP90 and prevents proteasome degradation. This allows LPTs to avoid apoptosis. Strategies to restore apoptosis to these cells might be developed to treat patients with Crohn's disease.
BACKGROUND & AIMS: Defective apoptosis of lamina propria T cells (LPTs) is involved in the pathogenesis of Crohn's disease. Survivin, a member of the inhibitors of apoptosis family, prevents cell death and regulates cell division. Survivin has been studied extensively in cancer, but little is known about its role in Crohn's disease. METHODS:LPTs were isolated from mucosal samples of patients with Crohn's disease or ulcerative colitis and healthy individuals (controls). LPTs were activated with interleukin-2 or via CD3, CD2, and CD28 signaling, and cultured at 42°C to induce heat shock. Survivin expression was assessed by immunohistochemistry, confocal microscopy, and immunoblotting; survivin levels were reduced by RNA interference. Cell viability, apoptosis, and proliferation were measured by trypan blue exclusion, annexin-V/7-Aminoactinomycin D staining, and uptake of [3]thymidine, respectively. RESULTS:LPTs from patients with Crohn's disease had higher levels of survivin than LPTs from patients with ulcerative colitis or controls. RNA knockdown of survivin in LPTs inhibited their proliferation and promoted apoptosis. Levels of survivin were low in LPTs from patients with ulcerative colitis and controls as a result of ubiquitin-mediated proteasome degradation. In LPTs from patients with Crohn's disease, survivin bound to the heat shock protein (HSP)90, and therefore was resistant to proteasome degradation. Incubating LPTs with 17-N-allylamino-17-demethoxygeldanamycin, an inhibitor of HSP90, reduced levels of survivin and induced apoptosis. CONCLUSIONS: Levels of survivin are increased in LPTs from patients with Crohn's disease (compared with ulcerative colitis and controls) because survivin interacts with HSP90 and prevents proteasome degradation. This allows LPTs to avoid apoptosis. Strategies to restore apoptosis to these cells might be developed to treat patients with Crohn's disease.
Authors: Vassiliki Poulaki; Eirini Iliaki; Nicholas Mitsiades; Constantine S Mitsiades; Yiannis N Paulus; Deisy V Bula; Evangelos S Gragoudas; Joan W Miller Journal: FASEB J Date: 2007-03-30 Impact factor: 5.191
Authors: Achim Temme; Jose A Rodriguez; Sandy Hendruschk; Serap Günes; Bernd Weigle; Knut Schäkel; Marc Schmitz; Michael Bachmann; Gabriele Schackert; E Peter Rieber Journal: Cancer Lett Date: 2006-11-07 Impact factor: 8.679
Authors: Alexander Visekruna; Thorsten Joeris; Daniel Seidel; Anjo Kroesen; Christoph Loddenkemper; Martin Zeitz; Stefan H E Kaufmann; Ruth Schmidt-Ullrich; Ulrich Steinhoff Journal: J Clin Invest Date: 2006-11-22 Impact factor: 14.808
Authors: Arthur Kaser; Ann-Hwee Lee; Andre Franke; Jonathan N Glickman; Sebastian Zeissig; Herbert Tilg; Edward E S Nieuwenhuis; Darren E Higgins; Stefan Schreiber; Laurie H Glimcher; Richard S Blumberg Journal: Cell Date: 2008-09-05 Impact factor: 41.582
Authors: Valeria Cohran; Elizabeth Managlia; Emily M Bradford; Tatiana Goretsky; Ting Li; Rebecca B Katzman; Paul Cheresh; Jeffrey B Brown; Jennifer Hawkins; Shirley X L Liu; Isabelle G De Plaen; Jörn-Hendrik Weitkamp; Michael Helmrath; Zheng Zhang; Terrence A Barrett Journal: Am J Pathol Date: 2016-05-06 Impact factor: 4.307
Authors: Minna Turkkila; Karin M E Andersson; Sylvie Amu; Mikael Brisslert; Malin C Erlandsson; Sofia Silfverswärd; Maria I Bokarewa Journal: Arthritis Res Ther Date: 2015-07-10 Impact factor: 5.156
Authors: Annelies W Turksma; Hetty J Bontkes; Janneke J Ruizendaal; Kirsten B J Scholten; Johanneke Akershoek; Shakila Rampersad; Laura M Moesbergen; Saskia A G M Cillessen; Saskia J A M Santegoets; Tanja D de Gruijl; C René Leemans; Chris J L M Meijer; Erik Hooijberg Journal: J Transl Med Date: 2013-06-20 Impact factor: 5.531